Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Regen Biopharma ( (RGBP) ) has shared an update.
Between February 4, 2026 and February 27, 2026, Regen Biopharma issued 77,849,847 common shares to retire $53,474 of principal on convertible debt, $4,249 of accrued interest, and $11,000 in related fees, with the transaction conducted as a private offering under Section 4(a)(2) of the Securities Act of 1933. The shares were sold directly by management without underwriters, commissions, or general solicitation, and as of March 3, 2026, the company’s total common shares outstanding increased to 212,318,424, signaling further equity dilution as part of its balance-sheet management.
More about Regen Biopharma
Regen Biopharma operates in the biotechnology and life sciences sector, focusing on developing therapeutic products based on cellular and molecular technologies. The company accesses capital markets through equity issuance and convertible debt, reflecting a financing strategy common among early-stage or development-focused biotech firms.
Average Trading Volume: 466,712
Technical Sentiment Signal: Strong Sell
Current Market Cap: $142.4K
For an in-depth examination of RGBP stock, go to TipRanks’ Overview page.